KGF/FGF-7 蛋白, Human

KGF/FGF-7 Protein is an epithelial cell-specific mitogen secreted by normal stromal fibroblasts. KGF/FGF-7 Protein activates plasminogen activator (PA) activity to promote extracellular matrix degradation. KGF/FGF-7 Protein, Human has activities such as promoting the proliferation and differentiation of epithelial cells (such as keratinocytes, thymic epithelial cells), repairing tissue damage (such as intestinal ischemia/reperfusion injury, bone defects), and regulating immune function (such as improving thymus function in aged mice). KGF/FGF-7 Protein, Human is a recombinant KGF/FGF-7 protein expressed by E. coli without a tag.

KGF/FGF-7 Protein 属于成纤维细胞生长因子家族^[1]。KGF/FGF-7 Protein 是由正常基质成纤维细胞分泌的上皮细胞特异性有丝分裂原^[1]。KGF/FGF-7 Protein 通过与上皮细胞表面的特异性受体结合，刺激上皮细胞增殖、迁移，并调控分化过程，例如在高钙条件下促进角质细胞表达早期 (K1) 和晚期 (丝聚蛋白) 分化标志物，同时可激活纤溶酶原 activator (PA) 活性促进细胞外基质降解^[1][3]。KGF/FGF-7 Protein 在皮肤、胃肠道、肺、胸腺等多种组织的间质细胞中表达，通过旁分泌作用于上皮细胞^{[1][2][5][6][7]}。KGF/FGF-7 Protein, Human 具有促进上皮细胞 (如角质细胞、胸腺上皮细胞) 增殖分化、修复组织损伤 (如肠缺血/再灌注损伤、骨缺损)、调节免疫功能 (如改善衰老小鼠胸腺功能) 等活性，例如在伤口修复中刺激角质细胞迁移和 PA 活性，在骨缺损模型中促进成骨标志物表达和新骨形成^{[1][3][4][5][6][7]}。

KGF/FGF-7 Protein, Human (10 ng/mL; 4 天) 促进人角质形成细胞增殖，效果与 EGF 相当^[1]。
KGF/FGF-7 Protein, Human (20 ng/mL; 6-48 h) 诱导人 HaCaT 角质形成细胞 SCF mRNA 和蛋白分泌增加^[2]。
KGF/FGF-7 Protein, Human (1 nM; 16 h) 显著刺激人角质形成细胞迁移和尿激酶型纤溶酶原激活物 (uPA) 活性^[3]。
KGF/FGF-7 Protein, Human (25-200 ng/mL；迁移测试：48 h) 刺激大鼠骨髓基质细胞 (BMSCs) 迁移并增加 SDF-1 和 CXCR4 的表达^[4]。

KGF/FGF-7 Protein, Human (5 mg/kg; 皮下注射；3 天；移植前) 在 B10.BR 小鼠异基因骨髓移植模型中降低 GVHD 死亡率，改善肝、肺等器官损伤^[5]。
KGF/FGF-7 Protein, Human (5 mg/kg/d; 腹腔注射；5 天；术前) 在 C57BL/6J 小鼠肠缺血/再灌注模型中增加肠湿重，减少上皮凋亡，恢复紧密连接蛋白分布^[6]。
KGF/FGF-7 Protein, Human (5 mg/kg/d; 皮下注射；3 天) 在 C57BL/6J 小鼠中诱导胸腺再生，增加胸腺细胞数量及 naive T 细胞输出^[7]。

Measured in a cell proliferation assay using 4MBr-5 rhesus monkey epithelial cells.The ED₅₀ for this effect is ≤110.3 ng/mL, corresponding to a specific activity is ≥9.07×10³ U/mg.

• 
  Measured in a cell proliferation assay using 4MBr‑5 rhesus monkey epithelial cells.The ED₅₀ for this effect is 15.20 ng/mL, corresponding to a specific activity is 6.6×10⁴ U/mg.

Human

E. coli

Tag Free

P21781-1 (C32-T194)

2252  [NCBI]

Full Length of Isoform-1 Mature Protein

CNDMTPEQMATNVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT

Approximately 17.6-20 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of 20 mM Tris, 1mM EDTA, 5% Trehalose, 0.02% Tween 80, pH 8.0 or 50 mM Tris-HCL, 300 mM NaCL, pH 7.4 or PBS or 50 mM Tris-HCL, 300 mM NaCl, pH 8.0, 5% trehalose, 5% mannitol and 0.01% Tween80 or 20 mM PB, 500 mM NaCl, pH 8.0, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Marchese C, et al. Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J Cell Physiol. 1990 Aug;144(2):326-32.  [Content Brief]

  [2]. Belleudi F, et al. KGF Promotes Paracrine Activation of the SCF/c-KIT Axis from Human Keratinocytes to Melanoma Cells. Transl Oncol. 2010 Apr;3(2):80-90.  [Content Brief]

  [3]. Tsuboi R, et al. Keratinocyte growth factor (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. J Invest Dermatol. 1993 Jul;101(1):49-53.  [Content Brief]

  [4]. Poudel SB, et al. Local delivery of recombinant human FGF7 enhances bone formation in rat mandible defects. J Bone Miner Metab. 2017 Sep;35(5):485-496.  [Content Brief]

  [5]. Panoskaltsis-Mortari A, et al. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 1998 Nov 15;92(10):3960-7.  [Content Brief]

  [6]. Cai Y, et al. Keratinocyte growth factor improves epithelial structure and function in a mouse model of intestinal ischemia/reperfusion. PLoS One. 2012;7(9):e44772.  [Content Brief]

  [7]. Min D, et al. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood. 2007 Mar 15;109(6):2529-37.  [Content Brief]